{"transactions":[{"id":4615737,"issuer":{"id":7194,"kind":"organization","name":"SCYNEXIS INC","symbol":"SCYX"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-11T20:02:07.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option vests on the one-year anniversary of the grant date with the remainder vesting in equal monthly installments for thirty-six (36) months thereafter, provided the Reporting Person continues to provide continuous services to the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":4.91,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001790246-26-000005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1790246/000179024626000005/ownership.xml","form_type":"4"}},{"id":1092443,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:16:07.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"}],"balance_after":0,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950170-25-094103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094103/ownership.xml","form_type":"4"}},{"id":1092442,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:16:07.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":135000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"}],"balance_after":0,"derivative":{"exercise_price":3.3,"expiration_date":"2033-03-22","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0000950170-25-094103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094103/ownership.xml","form_type":"4"}},{"id":1092441,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:16:07.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option"}],"balance_after":0,"derivative":{"exercise_price":3.96,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0000950170-25-094103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094103/ownership.xml","form_type":"4"}},{"id":1092440,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Restricted Stock Units","published_at":"2025-07-03T19:16:07.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000950170-25-094103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094103/ownership.xml","form_type":"4"}},{"id":1092439,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Common Stock","published_at":"2025-07-03T19:16:07.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":false,"shares":39701,"price":4,"value":158804.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-094103","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025094103/ownership.xml","form_type":"4"}},{"id":1100251,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Common Stock","published_at":"2025-06-27T16:05:05.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":6813,"price":0.74,"value":5041.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period."}],"balance_after":39701,"source":{"system":"sec-edgar","filing":"0000950170-25-090862","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025090862/ownership.xml","form_type":"4"}},{"id":1183536,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO & Head of BD"}}],"security":"Common Stock","published_at":"2025-04-02T16:27:45.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":2490,"price":0.77,"value":1917.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of October 1, 2024 through March 31, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on March 31, 2025, the last trading day of the purchase period."}],"balance_after":32888,"source":{"system":"sec-edgar","filing":"0000950170-25-049386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025049386/ownership.xml","form_type":"4"}},{"id":1203776,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T16:26:41.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":38500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."}],"balance_after":38500,"derivative":{"underlying":"Common Stock","underlying_shares":38500},"source":{"system":"sec-edgar","filing":"0000950170-25-040323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025040323/ownership.xml","form_type":"4"}},{"id":1203775,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T16:26:41.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price represents the closing price of the Issuer's common stock on March 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":145000,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950170-25-040323","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017025040323/ownership.xml","form_type":"4"}},{"id":1574791,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-15T08:30:05.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":165000,"derivative":{"exercise_price":5.77,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0000950170-24-031876","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000095017024031876/ownership.xml","form_type":"4"}},{"id":1767567,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2023-10-03T16:05:26.000Z","date":"2023-09-29","kind":"grant","planned":false,"acquired":true,"shares":2319,"price":3.57,"value":8278.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2023 through September 30, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 29, 2023, the last trading day of the purchase period."}],"balance_after":30398,"source":{"system":"sec-edgar","filing":"0001209191-23-051393","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123051393/doc4.xml","form_type":"4"}},{"id":1928302,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2023-04-04T08:37:44.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":979,"price":2.21,"value":2163.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of October 1, 2022 through March 31, 2023. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 3, 2022, the first trading day of the purchase period."}],"balance_after":28079,"source":{"system":"sec-edgar","filing":"0001209191-23-022466","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123022466/doc4.xml","form_type":"4"}},{"id":1937918,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock option (right to buy)","published_at":"2023-03-27T16:05:22.000Z","date":"2023-03-23","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 23, 2023. The shares underlying the option are scheduled to vest in equal monthly installments from April 23, 2023 through March 23, 2027."}],"balance_after":135000,"derivative":{"exercise_price":3.3,"expiration_date":"2033-03-22","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-23-021202","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919123021202/doc4.xml","form_type":"4"}},{"id":2293932,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Common Stock","published_at":"2022-04-20T16:05:23.000Z","date":"2022-04-19","kind":"purchase","acquired":true,"shares":27100,"price":3.69,"value":99999.0,"ownership":{"direct":true},"balance_after":27100,"source":{"system":"sec-edgar","filing":"0001209191-22-024916","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919122024916/doc4.xml","form_type":"4"}},{"id":2321455,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO"}}],"security":"Stock option (right to buy)","published_at":"2022-03-22T16:11:28.000Z","date":"2022-03-21","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 21, 2022 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date."}],"balance_after":180000,"derivative":{"exercise_price":3.96,"expiration_date":"2032-03-20","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-22-020519","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693011/000120919122020519/doc4.xml","form_type":"4"}},{"id":2443027,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-06T00:33:00.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":454007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests annually in equal installments over three years commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":454007,"derivative":{"exercise_price":4.72,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":454007},"source":{"system":"sec-edgar","filing":"0001062993-22-000700","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000106299322000700/form4.xml","form_type":"4"}},{"id":2443026,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-06T00:33:00.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":125534,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Ocugen Inc.'s (the \"Company's\") common stock. The restricted stock units vest annually in three equal installments commencing on January 3, 2023, subject to continued employment with the Company on the applicable vesting dates. The restricted stock units will be settled on each applicable vesting date in shares of the Company's common stock."}],"balance_after":161125,"source":{"system":"sec-edgar","filing":"0001062993-22-000700","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000106299322000700/form4.xml","form_type":"4"}},{"id":2465506,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option(Right toBuy)","published_at":"2021-12-18T02:26:10.000Z","date":"2021-12-16","kind":"grant","acquired":true,"shares":35560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the closing price of Ocugen, Inc.'s (the \"Company\") common stock on the date of grant. See footnote 2 below."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the \"Performance-Based Option\"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's\ndetermination that the applicable criteria has been achieved (each, a \"Determination Date\") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date."},{"field":"shares","element":"transactionShares","label":"F3","text":"On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the \"Performance-Based Option\"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's\ndetermination that the applicable criteria has been achieved (each, a \"Determination Date\") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 16, 2021, the Compensation Committee determined that the second performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on December 16, 2022, subject to the Reporting Person's continued service with the Company."}],"balance_after":71120,"derivative":{"exercise_price":5.64,"expiration_date":"2031-04-19","underlying":"Common Stock","underlying_shares":35560},"source":{"system":"sec-edgar","filing":"0001104659-21-151346","document":"tm2135818-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465921151346/tm2135818-10_4seq1.xml","form_type":"4"}},{"id":2504472,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-11-18T21:01:35.000Z","date":"2021-11-16","kind":"grant","acquired":true,"shares":35560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the closing price of Ocugen, Inc.'s (the \"Company\") common stock on the date of grant. See footnote 2 below."},{"field":"shares","element":"transactionShares","label":"F2","text":"On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the \"Performance-Based Option\"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a \"Determination Date\") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On April 19, 2021, the Reporting Person was granted a performance-based option to purchase 177,800 shares of the Company's common stock based on the Company's satisfaction of five performance criteria prior to the end of the Company's 2021 and 2022 fiscal years, as applicable (the \"Performance-Based Option\"). With respect to each performance criteria, 10% of the Performance-Based Option vests on the date of the Compensation Committee's determination that the applicable criteria has been achieved (each, a \"Determination Date\") and an additional 10% vests upon the first anniversary of the applicable Determination Date, subject to the grantee's continued service with the Company on such date. On November 16, 2021, the Compensation Committee determined that one of the performance criteria had been achieved, resulting in the Performance-Based Option vesting in part as to 35,560 shares. 17,780 shares of the Performance-Based Option are immediately vested and exercisable, with the remaining 17,780 shares vesting on November 16, 2022, subject to the Reporting Person's continued service with the Company."}],"balance_after":35560,"derivative":{"exercise_price":5.64,"expiration_date":"2031-04-19","underlying":"Common Stock","underlying_shares":35560},"source":{"system":"sec-edgar","filing":"0001192482-21-000754","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000754/edgar.xml","form_type":"4"}},{"id":2533442,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-27T21:09:12.000Z","date":"2021-10-26","kind":"sale","acquired":false,"shares":10000,"price":11.07,"value":110700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":35591,"source":{"system":"sec-edgar","filing":"0001879785-21-000013","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000187978521000013/edgar.xml","form_type":"4"}},{"id":2541418,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-10-15T20:01:51.000Z","date":"2021-10-15","kind":"exercise","acquired":false,"shares":7990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, initially representing a right to purchase a total of 23,970 shares, vests and becomes exercisable in equal annual installments over a three year period commencing on October 1, 2020, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":7990,"derivative":{"exercise_price":2.19,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":7990},"source":{"system":"sec-edgar","filing":"0001192482-21-000740","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000740/edgar.xml","form_type":"4"}},{"id":2541417,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-15T20:01:51.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":7990,"price":9.96,"value":79580.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.96 to $9.97.  The Reporting Person undertakes to provide Ocugen, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000740","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000740/edgar.xml","form_type":"4"}},{"id":2541416,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-15T20:01:51.000Z","date":"2021-10-15","kind":"exercise","acquired":true,"shares":7990,"price":2.19,"value":17498.1,"ownership":{"direct":true},"balance_after":53581,"source":{"system":"sec-edgar","filing":"0001192482-21-000740","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000740/edgar.xml","form_type":"4"}},{"id":2597445,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-08-18T20:01:49.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":246170,"derivative":{"exercise_price":0.34,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001192482-21-000669","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000669/edgar.xml","form_type":"4"}},{"id":2597444,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T20:01:49.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":30000,"price":7.22,"value":216600.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.18 to $7.28.  The Reporting Person undertakes to provide Ocugen, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000669","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000669/edgar.xml","form_type":"4"}},{"id":2597443,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T20:01:49.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":30000,"price":0.34,"value":10200.0,"ownership":{"direct":true},"balance_after":75591,"source":{"system":"sec-edgar","filing":"0001192482-21-000669","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000669/edgar.xml","form_type":"4"}},{"id":2631740,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2021-07-16T20:01:18.000Z","date":"2021-07-15","kind":"exercise","acquired":false,"shares":31086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options, initially representing a right to purchase a total of 369,256 shares, vest and become exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":276170,"derivative":{"exercise_price":0.34,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":31086},"source":{"system":"sec-edgar","filing":"0001192482-21-000633","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000633/edgar.xml","form_type":"4"}},{"id":2631739,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-16T20:01:18.000Z","date":"2021-07-15","kind":"sale","acquired":false,"shares":31086,"price":6.7,"value":208276.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.66 to $6.77.  The Reporting Person undertakes to provide Ocugen, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000633","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000633/edgar.xml","form_type":"4"}},{"id":2631738,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-07-16T20:01:18.000Z","date":"2021-07-15","kind":"exercise","acquired":true,"shares":31086,"price":0.34,"value":10569.24,"ownership":{"direct":true},"balance_after":76677,"source":{"system":"sec-edgar","filing":"0001192482-21-000633","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000633/edgar.xml","form_type":"4"}},{"id":2663200,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-06-17T21:25:01.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":307256,"derivative":{"exercise_price":0.34,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001790246-21-000003","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000179024621000003/edgar.xml","form_type":"4"}},{"id":2663199,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T21:25:01.000Z","date":"2021-06-15","kind":"sale","acquired":false,"shares":31000,"price":7,"value":217000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $6.96 to $7.07, inclusive."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001790246-21-000003","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000179024621000003/edgar.xml","form_type":"4"}},{"id":2663198,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T21:25:01.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":31000,"price":0.34,"value":10540.0,"ownership":{"direct":true},"balance_after":76591,"source":{"system":"sec-edgar","filing":"0001790246-21-000003","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000179024621000003/edgar.xml","form_type":"4"}},{"id":2711981,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-05-14T20:58:44.000Z","date":"2021-05-14","kind":"exercise","acquired":false,"shares":31000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option, initially representing a right to purchase a total of 369,256 shares, vests and becomes exercisable in equal annual installments over a three year period, commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":338256,"derivative":{"exercise_price":0.34,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":31000},"source":{"system":"sec-edgar","filing":"0001192482-21-000423","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000423/edgar.xml","form_type":"4"}},{"id":2711980,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-14T20:58:44.000Z","date":"2021-05-14","kind":"sale","acquired":false,"shares":31000,"price":8.183,"value":253673.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.15 to $8.24.  The Reporting Person undertakes to provide Ocugen, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000423","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000423/edgar.xml","form_type":"4"}},{"id":2711979,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-14T20:58:44.000Z","date":"2021-05-14","kind":"exercise","acquired":true,"shares":31000,"price":0.34,"value":10540.0,"ownership":{"direct":true},"balance_after":76591,"source":{"system":"sec-edgar","filing":"0001192482-21-000423","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000423/edgar.xml","form_type":"4"}},{"id":2732670,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-05-04T01:06:27.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":7990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"7,990 shares under the option are exercisable. The option, initially representing a right to purchase a total of 23,970 shares, vests and becomes exercisable in equal annual installments over a three year period."}],"balance_after":15980,"derivative":{"exercise_price":2.19,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":7990},"source":{"system":"sec-edgar","filing":"0001192482-21-000394","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000394/edgar.xml","form_type":"4"}},{"id":2732669,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-04T01:06:27.000Z","date":"2021-04-29","kind":"sale","acquired":false,"shares":7990,"price":10.98,"value":87730.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07.  The Reporting Person undertakes to provide Ocugen, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000394","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000394/edgar.xml","form_type":"4"}},{"id":2732668,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-04T01:06:27.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":7990,"price":2.19,"value":17498.1,"ownership":{"direct":true},"balance_after":53581,"source":{"system":"sec-edgar","filing":"0001192482-21-000394","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000394/edgar.xml","form_type":"4"}},{"id":2888330,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-02-01T22:31:45.000Z","date":"2021-01-29","kind":"exercise","acquired":false,"shares":35591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options to purchase one third of the shares (35,591 shares of common stock) vested on January 2, 2021. The remaining options will vest annually in equal installments on January 2, 2022 and January 2, 2023, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":71183,"derivative":{"exercise_price":0.51,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":35591},"source":{"system":"sec-edgar","filing":"0001192482-21-000125","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000125/edgar.xml","form_type":"4"}},{"id":2888329,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-01T22:31:45.000Z","date":"2021-01-29","kind":"exercise","acquired":true,"shares":35591,"price":0.51,"value":18151.41,"ownership":{"direct":true},"balance_after":45591,"source":{"system":"sec-edgar","filing":"0001192482-21-000125","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000125/edgar.xml","form_type":"4"}},{"id":2925118,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option (Right to Buy)","published_at":"2021-01-04T22:44:12.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests annually in equal installments over three years commencing on January 1, 2022, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":800000,"derivative":{"exercise_price":1.83,"expiration_date":"2031-01-01","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001192482-21-000021","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248221000021/edgar.xml","form_type":"4"}},{"id":3157801,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-05-07T23:58:33.000Z","date":"2020-05-05","kind":"grant","acquired":true,"shares":369256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest annually in equal installments over three years commencing on May 5, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":369256,"derivative":{"exercise_price":0.34,"expiration_date":"2030-05-05","underlying":"Common Stock","underlying_shares":369256},"source":{"system":"sec-edgar","filing":"0001192482-20-000329","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248220000329/edgar.xml","form_type":"4"}},{"id":3321884,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options (Right to Buy)","published_at":"2020-01-04T01:38:08.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":106774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest annually in equal installments over three years commencing on January 2, 2021, subject to continued employment with the Company on the applicable vesting dates."}],"balance_after":106774,"derivative":{"exercise_price":0.51,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":106774},"source":{"system":"sec-edgar","filing":"0001192482-20-000023","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248220000023/edgar.xml","form_type":"4"}},{"id":3358525,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-11-27T00:17:08.000Z","date":"2019-11-22","kind":"purchase","acquired":true,"shares":5000,"price":0.28,"value":1400.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001192482-19-000445","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000119248219000445/edgar.xml","form_type":"4"}},{"id":3397203,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2019-10-04T17:36:23.000Z","date":"2019-10-01","kind":"grant","acquired":true,"shares":23970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option grant has a ten year term and vests in equal installments on the anniversary date over a three year period."}],"balance_after":23970,"derivative":{"exercise_price":2.19,"expiration_date":"2029-10-01","underlying":"Common Stock","underlying_shares":23970},"source":{"system":"sec-edgar","filing":"0001104659-19-053097","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465919053097/a4.xml","form_type":"4"}},{"id":3397202,"issuer":{"id":5550,"kind":"organization","name":"Ocugen, Inc.","symbol":"OCGN"},"owners":[{"id":77719,"kind":"person","name":"Subramanian Sanjay","position":1,"cik":"0001790246","reported_name":"Subramanian Sanjay","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-10-04T17:36:23.000Z","date":"2019-10-02","kind":"purchase","acquired":true,"shares":5000,"price":1.88,"value":9400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option grant has a ten year term and vests in equal installments on the anniversary date over a three year period."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001104659-19-053097","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372299/000110465919053097/a4.xml","form_type":"4"}}]}